TP7.2.3 The effect of immediate versus early instillation of mitomycin C after transurethral resection of bladder cancer: Is timing everything?

Abstract Introduction and Aims Almost three quarters of patients diagnosed with bladder cancer have non-muscle invasive disease. The European Association Urology (EAU) guidelines recommend the use intravesical instillation Mitomycin C (MMC) to reduce rate recurrence. Methods A retrospective cohort analysis was carried out all who underwent a TURBT between January 2016 2019 in our Trust. comparison recurrence outcomes investigated had immediate MMC (within 1 hours post-TURBT) versus early 24 post-TURBT). Recurrence assessed at 3 months cystoscopy year follow-up. Results 201 were included. 100 (75% male, 25% female); 101 (72% 28% female). There 11% (immediate) 13% (early) groups months. At first year, seen 12% 14% groups. Of these recurrences, there an upstaging tumour 27% 31% monthly follow-up 1st year. mean period post-operative stay following initial 0.8 days 1.1 Conclusion Although no statistical differences this study, results appear favour after respect reduction rates. Post-operative length hospital also shorter instillation.